3-methyl-1-phenyl-1H-pyrazol-5-yl 6-(nitrooxy)hexanoate | 1357020-27-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-methyl-1-phenyl-1H-pyrazol-5-yl 6-(nitrooxy)hexanoate
• 英文别名: (5-Methyl-2-phenylpyrazol-3-yl) 6-nitrooxyhexanoate；(5-methyl-2-phenylpyrazol-3-yl) 6-nitrooxyhexanoate
• CAS: 1357020-27-9
• 化学式: C₁₆H₁₉N₃O₅
• 分子量: 333.344
• InChiKey: XKOMKPPZAYRFKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  99.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6-(nitrooxy)hexanoic acid 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 1.0h， 生成 3-methyl-1-phenyl-1H-pyrazol-5-yl 6-(nitrooxy)hexanoate
  参考文献：
  名称：

  Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs

  摘要：

  A new class of co-drugs were synthesised by joining antioxidant edaravone with a vasodilating substructure containing NO-donor nitrooxy functions, and characterised for their stability in different media, lipophilicity and permeability profile. The products display good stability in water/co-solvent at different pH. Conversely, they are rapidly metabolised into edaravone and NO-donor moieties when incubated in human serum or rat-liver homogenates. In the latter conditions time dependent production of nitrite/nitrate (NOx) occurs. The compounds display wide-ranging lipophilicity. PAMPA studies predict good gastrointestinal absorption for a number of these compounds. The title products are potentially useful for treating ROS-related conditions accompanied by decreased NO availability. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.065

文献信息

• Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs
  作者：Barbara Rolando、Andrea Filieri、Konstantin Chegaev、Loretta Lazzarato、Marta Giorgis、Claudio De Nardi、Roberta Fruttero、Sophie Martel、Pierre-Alain Carrupt、Alberto Gasco

  DOI：10.1016/j.bmc.2011.11.065

  日期：2012.1

  A new class of co-drugs were synthesised by joining antioxidant edaravone with a vasodilating substructure containing NO-donor nitrooxy functions, and characterised for their stability in different media, lipophilicity and permeability profile. The products display good stability in water/co-solvent at different pH. Conversely, they are rapidly metabolised into edaravone and NO-donor moieties when incubated in human serum or rat-liver homogenates. In the latter conditions time dependent production of nitrite/nitrate (NOx) occurs. The compounds display wide-ranging lipophilicity. PAMPA studies predict good gastrointestinal absorption for a number of these compounds. The title products are potentially useful for treating ROS-related conditions accompanied by decreased NO availability. (C) 2011 Elsevier Ltd. All rights reserved.